Presentations by Event

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad-spectrum activity against Class A, C and D enzymes

Alita Miller, Superbugs & Superdrugs USA 2016

Program(s): durlobactam (etx2514)

Microbiological Cure Rates and Antimicrobial Susceptibility of Neisseria gonorrhoeae to ETX0914 (AZD0914) in a Phase II Treatment Trial for Urogenital Gonorrhea

Stephanie N. Taylor, MD; LSU-Crescent Care Sexual Health Center, ID Week 2016

Program(s): zoliflodacin (etx0914)

Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase Inhibitor ETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014

Kenneth Lawrence, ID Week 2016

Program(s): durlobactam (etx2514)

Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii

John O’Donnell, ID Week 2016

Program(s): durlobactam (etx2514)

Sulbactam Combined with the Novel β–lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Alita Miller, ID Week 2016

Program(s): durlobactam (etx2514)

ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C and D β–lactamases, for the Treatment of Gram-negative Infections

Adam Shapiro, ASM Microbe 2016

Program(s): durlobactam (etx2514)

A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea

Ken Lawrence, ASM Microbe 2016

Addressing the Evolving Challenge of β-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes

Ruben Tommasi, ASM Microbe 2016

Program(s): durlobactam (etx2514)

In Vitro and In Vivo Efficacy of the Novel β-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii

John O’Donnell, ASM Microbe 2016

Program(s): durlobactam (etx2514)